In this issue:
Responses to biological agents in moderate-severe psoriasis
Mental health comorbidity in psoriasis
Hypercalcaemia with calcipotriol hydrate/betamethasone dipropionate
Low-dose infliximab in psoriatic arthritis
Asian consensus on topical therapy in mild-to-moderate plaque psoriasis
Real-world health outcomes in moderate-to-severe psoriasis in the US
Persistence and medical costs of biologicals in Japan
Intra- and inter-observer variability in image-based PASI assessment
Itch and other psoriasis symptoms with brodalumab
IL-17A and IL-17F neutralisation with bimekizumab
Certolizumab pegol for chronic plaque psoriasis
JAK-1 inhibitor PF-04965842 for moderate-to-severe psoriasis
Please login below to download this issue (PDF)